Login to Your Account



Looking Long on SGEN

CD20 v. CD30: Will SeaGen's Adcetris Be the Next Rituxan?

By Trista Morrison


Monday, August 29, 2011
With this month's FDA approval of Adcetris (brentuximab vedotin), Seattle Genetics Inc. can lay claim to many firsts: first commercial product for the Bothell, Wash.-based biotech, first new drug for Hodgkin lymphoma patients in more than 30 years, first antibody-drug conjugate to gain FDA approval and first anti-CD30-targeted therapy approved. (See BioWorld Today, Aug. 22, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription